TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25602908

Group type: EXPERIMENTAL
Intervention: Advance notification letter (B)
Number of subjects: 39198

Group type: EXPERIMENTAL
Intervention: Advance notification letter followed by standard invitation (C)
Number of subjects: 39198

Group type: COMPARATOR
Intervention: Standard invitation letter (A)
Number of subjects: 39198

Group type: EXPERIMENTAL
Intervention: Advance notification letter (C)
Number of subjects: 39198
Study: 24016559

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Lidocaine and hormone
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ginaton
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ginaton and hormone
Number of subjects: 141
Study: 21477136

Group type: EXPERIMENTAL
Intervention: N95 respirators (fit tested)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: N95 respirators (non-fit tested)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Convenience no-mask group
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: N95 masks and hospital level
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Medical masks, vaccination, handwashing, high-risk procedures
Number of subjects: 1441
Study: 19141586

Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RU38486 (400 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined spironolactone (200 mg) + RU38486 (400 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17729000

Group type: EXPERIMENTAL
Intervention: 5M CRT monitor
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3M LCD monitor
Number of subjects: 100
Study: 10942064

Group type: EXPERIMENTAL
Intervention: CMB-401 (dosing commenced at 2 mg/m2 and progressed to 16 mg/m2 over seven cohorts)
Number of subjects: 34
Study: 8843892

Group type: EXPERIMENTAL
Intervention: Pravastatin (15 mg) for 12 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 1387739

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 62
Study: 6565475

Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional therapy for ten days
Number of subjects: 36
Study: 31033900

Group type: COMPARATOR
Intervention: Concentric Resistance Training (CNC RT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Eccentric Resistance Training (ECC RT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Wait-list, no-exercise control group
Number of subjects: 90
Study: 30088607

Group type: EXPERIMENTAL
Intervention: Patent haemostasis with TR Band™ device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional haemostasis with an elastic adhesive bandage
Number of subjects: 0
Study: 27091830

Group type: EXPERIMENTAL
Intervention: Nurse-delivered smoking abstinence intervention (intensity varied by risk group)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group (smoking abstinence booklet plus newsletters about parenting and stress)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 382
Study: 25104497

Group type: EXPERIMENTAL
Intervention: Glucocorticoid blockade using RU38486 (mifepristone) and metyrapone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study: 22424008

Group type: EXPERIMENTAL
Intervention: CSS (Clinical Synergy Between PCI With Taxus and Cardiac Surgery score)
Number of subjects: 2094

Group type: EXPERIMENTAL
Intervention: NERS (New Risk Stratification score)
Number of subjects: 2094

Group type: EXPERIMENTAL
Intervention: SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery score)
Number of subjects: 2094

Group type: EXPERIMENTAL
Intervention: CSS and NERS
Number of subjects: 2094
Study: 20421752

Group type: EXPERIMENTAL
Intervention: 1-day spiritual retreat
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (no retreat)
Number of subjects: 199
Study: 17415205

Group type: EXPERIMENTAL
Intervention: Less than 90 Gy with no selective beam channel blocking (Group 1)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 90 Gy with no selective beam channel blocking (Group 2)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 90 Gy with selective beam channel blocking (Group 3)
Number of subjects: 358
Study: 15625212

Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12407605

Group type: EXPERIMENTAL
Intervention: High-dose AF0144 (2.7 g/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-dose AF0144 (1.8 g/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AF0144
Number of subjects: 36
Study: 10501521

Group type: EXPERIMENTAL
Intervention: Voluntary movements of the stimulated hand
Number of subjects: 2
Study: 7474322

Group type: EXPERIMENTAL
Intervention: Finapres during rewarming
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nitroglycerin-assisted rewarming
Number of subjects: 16
Study: 2180749

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (short exposure before insemination)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (long exposure before insemination)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control semen
Number of subjects: 57
Study: 31187784

Group type: EXPERIMENTAL
Intervention: Overweight (defined as BMI for age and gender above +1 and below +2 SD scores)
Number of subjects: 7930

Group type: EXPERIMENTAL
Intervention: Obesity (defined as BMI for age and gender above +2 SD scores)
Number of subjects: 7930

Group type: COMPARATOR
Intervention: Comparison with WHO-based national prevalence rate of obesity reported in 2004
Number of subjects: 7930

Group type: COMPARATOR
Intervention: Age group comparison (adolescents vs children)
Number of subjects: 7930

Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 7930

Group type: EXPERIMENTAL
Intervention: Risk of developing gas bloating and vomiting
Number of subjects: 7930
Study: 27012728

Group type: EXPERIMENTAL
Intervention: Atenolol (β1-selective adrenergic blockade)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective adrenergic blockade)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study: 27144828

Group type: EXPERIMENTAL
Intervention: Stem cells cultured on β‐TCP in combination with rh‐PDGF‐BB
Number of subjects: 14

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 14
Study: 24080653

Group type: EXPERIMENTAL
Intervention: motavizumab‐YTE (0.3, 3, 15, or 30 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: motavizumab
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: motavizumab‐YTE
Number of subjects: 31

Group type: COMPARATOR
Intervention: motavizumab‐YTE and motavizumab
Number of subjects: 31
Study: 21747321

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control group (full-term infants)
Number of subjects: 313
Study: 20715888

Group type: EXPERIMENTAL
Intervention: Computerized working memory training for 5 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 17146738

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: D3 lymphadenectomy
Number of subjects: 523
Study: 14768922

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% with sufentanil 0.75 microg mL(‐1)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Ropivacaine 0.125% with sufentanil 0.75 microg mL(‐1)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.175% with sufentanil
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% without sufentanil
Number of subjects: 450
Study: 12899372

Group type: EXPERIMENTAL
Intervention: Psychopaths
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nonpsychopaths
Number of subjects: 67
Study: 9667592

Group type: EXPERIMENTAL
Intervention: Intraepidermal nerve fiber (IENF) density assessment via punch biopsy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sural nerve biopsy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clinical assessment of neuropathic pain
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Punch skin biopsy from proximal and distal sites
Number of subjects: 32
Study: 8596746

Group type: EXPERIMENTAL
Intervention: Health resort treatment
Number of subjects: 15
Study: 2788001

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with naloxone (50 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation with saline (placebo)
Number of subjects: 11
Study: 358815

Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous digoxin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1.0 mg intravenous digoxin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1.5 mg intravenous digoxin
Number of subjects: 9
Study: 31266043

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 90
Study: 28494047

Group type: EXPERIMENTAL
Intervention: Immediately Loaded Implants (IL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed Loaded Nonsubmerged Implants (NS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Delayed Loaded Submerged Implants (SI)
Number of subjects: 15
Study: 26883612

Group type: EXPERIMENTAL
Intervention: 5.25 percent Sodium Hypochlorite (NaOCl)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ferric Sulfate (FS)
Number of subjects: 81
Study: 23849964

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control Group (chronic statin therapy without reloading)
Number of subjects: 350
Study: 21729881

Group type: EXPERIMENTAL
Intervention: rs2108622 on 19pter‐p13.11
Number of subjects: 5006

Group type: EXPERIMENTAL
Intervention: rs11057830 on 12q24.31
Number of subjects: 5006

Group type: EXPERIMENTAL
Intervention: rs964184 on 11q23.3
Number of subjects: 5006

Group type: EXPERIMENTAL
Intervention: Combined meta-analysis
Number of subjects: 5006

Group type: EXPERIMENTAL
Intervention: Combined SNPs
Number of subjects: 5006

Group type: COMPARATOR
Intervention: GWAS cohort (n= 992)
Number of subjects: 5006
Study: 19712448

Group type: EXPERIMENTAL
Intervention: Standardised O&M-training in using the identification cane
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care O&M-training
Number of subjects: 190
Study: 16448524

Group type: EXPERIMENTAL
Intervention: Glimepiride (2 mg/day) plus metformin (1500 mg/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) plus metformin (1500 mg/day)
Number of subjects: 99
Study: 12632526

Group type: EXPERIMENTAL
Intervention: formula of amino acid enriched BCAA (BCAA group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: formula of amino acid (AA group)
Number of subjects: 40
Study: 10697061

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg twice daily
Number of subjects: 629

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Combined oseltamivir recipients
Number of subjects: 629
Study: 9333108

Group type: EXPERIMENTAL
Intervention: Norepinephrine (ED50) in parents
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Norepinephrine (ED50) in children
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Heritability estimation
Number of subjects: 44
Study: 8222517

Group type: EXPERIMENTAL
Intervention: 5% glucose polymer solution (272 +/- 1.1 mosmol/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 7.5% glucose polymer solution (277 +/- 2.0 mosmol/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 1.36% glucose solution (339 +/- 1.9 mosmol/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 2.27% glucose solution (393 +/- 3.2 mosmol/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10% glucose polymer solution (284 +/- 2.0 mosmol/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 3.86% glucose solution (482 +/- 1.6 mosmol/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 7.5% glucose polymer solution with 0.35% glucose
Number of subjects: 11
Study: 3774833

Group type: EXPERIMENTAL
Intervention: Marijuana smoking (placebo or 1.29%, 2.84%, 4.00%)
Number of subjects: 0
Study: 30515390

Group type: EXPERIMENTAL
Intervention: Coconut water (2L daily for 4 days)
Number of subjects: 8
Study: 26167946

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Present-centered therapy
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Dissociative symptoms
Number of subjects: 284
Study: 24388435

Group type: EXPERIMENTAL
Intervention: Specific temporal training (TT, n=11)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control non-temporal training (NT, n=7)
Number of subjects: 18
Study: 22575312

Group type: EXPERIMENTAL
Intervention: In-hospital ST
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Out-of-hospital ST
Number of subjects: 3602
Study: 20485707

Group type: EXPERIMENTAL
Intervention: Lidocaine plus xylometazoline (LX)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Lidocaine (L)
Number of subjects: 181
Study: 18400028

Group type: EXPERIMENTAL
Intervention: Orthodontic movement of 29 pre-molars for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group of 18 contralateral pre-molars not subjected to orthodontic movement
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Assessment of periodontal parameters (Plaque Index, Gingival Index, probing depth, bleeding on probing)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Assessment of relationship between resorption and periodontal parameters
Number of subjects: 16
Study: 16083628

Group type: EXPERIMENTAL
Intervention: Vitamin treatment (group A, n = 18, folic acid 5 mg/d, vitamin B(6) 50 mg/d, B(12) 1000 microg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (group B, n = 18)
Number of subjects: 36
Study: 12064916

Group type: EXPERIMENTAL
Intervention: Deferiprone (75 mg/kg/day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Deferoxamine (50 mg/kg/day)
Number of subjects: 144
Study: 9793811

Group type: EXPERIMENTAL
Intervention: Clonidine 5 mcg/kg (C5)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 mcg/kg (C2.5)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diazepam 100 mcg/kg (D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 80
Study: 7543785

Group type: EXPERIMENTAL
Intervention: Fotemustine (FM) 100 mg/m2 on days 1 + 8 + 15, followed by maintenance courses (q3w)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fotemustine (FM)
Number of subjects: 54
Study: 2696659

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime
Number of subjects: 296

Group type: COMPARATOR
Intervention: Ranitidine 300 mg single dose
Number of subjects: 296
Study: 825895

Group type: EXPERIMENTAL
Intervention: 1000 mug TRH (thyrotropin releasing hormone) by slow, continuous infusion over 4 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28691141

Group type: EXPERIMENTAL
Intervention: Vinpocetine (30 mg per day intravenously for 14 consecutive days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard management alone (controls)
Number of subjects: 60
Study: 26810358

Group type: EXPERIMENTAL
Intervention: Tailored interactive multimedia Internet intervention program (UV4.me)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Website of a skin cancer organization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 0
Study: 24677117

Group type: COMPARATOR
Intervention: Clopidogrel alone (300‐mg loading dose, then 75 mg/day for 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus omeprazole 80 mg, esomeprazole 40 mg or lansoprazole 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus esomeprazole 20 mg/low‐dose acetylsalicylic acid (ASA) 81 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel alone (75 mg/day for 9 days)
Number of subjects: 0
Study: 21538678

Group type: EXPERIMENTAL
Intervention: Internet insomnia intervention (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control group (n = 14)
Number of subjects: 28
Study: 20121770

Group type: EXPERIMENTAL
Intervention: 0.11 ml.mm(‐2) cross‐sectional nerve area with mepivacaine 1% (low volume)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.4 ml.mm(‐2) cross‐sectional nerve area with mepivacaine 1% (high volume)
Number of subjects: 10
Study: 17505917

Group type: EXPERIMENTAL
Intervention: Enhanced intervention for HIV prevention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 16181932

Group type: EXPERIMENTAL
Intervention: Strength training (12 weeks, 2 times a week, 1 set of 8 to 12 repetitions at 40% to 60% of maximal lifts, progressed to 60% to 80%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (wait-listed for exercise)
Number of subjects: 29
Study: 11978714

Group type: EXPERIMENTAL
Intervention: Mailed questionnaire about erectile dysfunction (ED) sent to the study population.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (no questionnaire sent).
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Mailed questionnaire about ED.
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Consultation with family doctor after questionnaire.
Number of subjects: 205
Study: 10478149

Group type: EXPERIMENTAL
Intervention: ELISA with manufacturer recommended cutoff (CO)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: ELISA with increased cutoff value (2CO)
Number of subjects: 277
Study: 8942514

Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile at 26 weeks
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile at 19 weeks
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile at 36 weeks
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Ferritin levels in the highest quartile
Number of subjects: 580
Study: 10145587

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests from 13 laboratories
Number of subjects: 5
Study: 6121043

Group type: EXPERIMENTAL
Intervention: Intravenous injection of lorazepam (2 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of lorazepam (2 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral lorazepam (2 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (2 mg) from oral tablets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (2 mg) from specially formulated tablets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular, oral, and sublingual lorazepam (2 mg)
Number of subjects: 10
Study: 30666098

Group type: EXPERIMENTAL
Intervention: Hearing aids and auditory training for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hearing aids
Number of subjects: 40
Study: 28925529

Group type: EXPERIMENTAL
Intervention: Isocapnic CPT (controlled P ET ,CO2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Poikilocapnic CPT (uncontrolled P ET ,CO2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isocapnic CPT
Number of subjects: 15

Group type: COMPARATOR
Intervention: Poikilocapnic CPT
Number of subjects: 15
Study: 25504269

Group type: EXPERIMENTAL
Intervention: Catheter ablation for AF in patients with ASD
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (matched subjects without ASD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Left atrial diameter in non-recurrent patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Left atrial diameter as a factor in arrhythmia recurrences
Number of subjects: 18
Study: 24756903

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) therapy
Number of subjects: 68
Study: 22381040

Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1656
Study: 20802325

Group type: EXPERIMENTAL
Intervention: Surrogate consent acceptance
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Surrogate consent acceptance criteria
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Limits on research risks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Risk limits with potential benefit
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Procedures to determine capacity
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Use of independent monitors and proxies
Number of subjects: 104
Study: 17445955

Group type: EXPERIMENTAL
Intervention: HPV-16 vaccine (three-dose regimen)
Number of subjects: 50
Study: 16226164

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 2885

Group type: COMPARATOR
Intervention: Standard statin therapy
Number of subjects: 2885
Study: 12236023

Group type: EXPERIMENTAL
Intervention: SB-LOT (90 mg coumarin and 540 mg troxerutin per day)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: SB-LOT
Number of subjects: 231
Study: 10101819

Group type: EXPERIMENTAL
Intervention: Transpedicular instrumentation
Number of subjects: 71

Group type: COMPARATOR
Intervention: No transpedicular instrumentation (Control)
Number of subjects: 71
Study: 7576400

Group type: EXPERIMENTAL
Intervention: Low salt intake (20 mmol sodium/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: High salt intake (300 mmol sodium/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Salt-sensitive subjects
Number of subjects: 46
Study: 2405915

Group type: EXPERIMENTAL
Intervention: Vasopressin nasal spray administered q.i.d. from the first through the fifth ECT
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33